People’s Doctor, Pharmacist Trần Thị Đào, General Director of Imexpharm, affirmed: "Initially Committed” to Community Health has always been the cornerstone of Imexpharm's business philosophy. We are dedicated to transparency and accuracy in financial reporting and business operations, ensuring the quality of our products, customer services, and prioritizing public health and the long-term interests of our shareholders and strategic investors."
Mr. Juerg Vontobel, Chairman of the fund management company Vietnam Holding, emphasized: "Imexpharm's management demonstrates a remarkably open and straightforward approach, which is rare among Vietnamese companies at this stage. Vietnam Holding highly values the company's transparency in dealings with partners and stakeholders."
Imexpharm was among the first pharmaceutical companies in Vietnam to achieve GMP certification in 1997. The company has maintained annual revenue and profit growth rates of 20%–30%. According to AC Nielsen's research in August 2007, Imexpharm ranked as one of the highest-quality pharmaceutical brands in Vietnam, widely trusted by doctors, pharmacists, and consumers.
The quality of Imexpharm's pharmaceutical products is rigorously validated by the National Institute for Drug Quality Control in Vietnam. Additionally, its quality management system is recognized as equivalent to international standards by multinational pharmaceutical corporations.
Imexpharm is Vietnam’s first and only franchised manufacturer for leading companies in the Betalactam antibiotic sector, including Biochemie (now Sandoz) and other firms like BD Pharma (France), Innotech (France), and Robinson (USA). Soon, Imexpharm will collaborate with Pharmascience Canada. In 2008, Imexpharm and Pharmascience Canada established a joint venture factory in Bình Dương, marking a significant milestone in Imexpharm's journey to becoming the m
ost reputable pharmaceutical manufacturer for global corporations in Vietnam.
The signing of agreements with strategic investors, Vietnam Holding and the VietFund Management joint-venture company, marked a pivotal moment in Imexpharm's growth.
Strategic partnership investment
Imexpharm aims to leverage the experience and management expertise of these investors, who will offer valuable guidance in its journey to becoming a trusted pharmaceutical manufacturer for global corporations in Vietnam. In turn, the investors will play a pivotal role in driving Imexpharm's growth by providing support in strategic planning, financial management, and human resource development.
Under the strategic partnership agreement, Vietnam Holding committed to purchasing 6% of Imexpharm's charter capital, pledging to hold this stake for many years while sharing management expertise. Representatives from VF2 and Vietnam Holding highlighted three main reasons for investing in Imexpharm: First, Imexpharm has a competent and experienced management team that has established the company as one of Vietnam's top three pharmaceutical manufacturers. Second, operating in a pharmaceutical sector that has grown at an average annual rate of nearly 15% over the past five years, Imexpharm is well-positioned for continued strong growth in the years ahead. Third, VF2 and Vietnam Holding can add value to Imexpharm by sharing expertise in key areas such as corporate finance and governance, making the company more attractive to investors.
Mr. Juerg Vontobel noted that Vietnam Holding’s network with global pharmaceutical companies in the US, Europe, and particularly Switzerland, could open new opportunities for Imexpharm to engage with additional strategic partners. With its proven leadership, focused business strategies, and consistent execution, Vietnam Holding believes Imexpharm is well-equipped to seize new growth opportunities and overcome emerging challenges in the market.
As a strategic shareholder, VF2 reiterated its long-term investment vision for both Imexpharm and Vietnam’s pharmaceutical industry. Beyond financial contributions, VF2 offers deep expertise through VietFund Management, which has successfully advised companies in its investment portfolio. VF2 is committed to supporting Imexpharm’s development through initiatives in strategic planning, investments, financial management, and human resources.
Vietnam’s leading franchised manufacturer
Imexpharm’s current strategic goal is rapid and robust development to become the leading franchised drug manufacturer for prestigious global pharmaceutical corporations in Vietnam and Southeast Asia.
Strategic partnerships with investment funds have significantly bolstered Imexpharm's financial capabilities. The company plans to implement several key projects worth nearly VND160 billion in 2008. These include the merger of the Đồng Tháp Mười Research, Conservation, and Medicinal Plant Development Center into Imexpharm. This project introduces a new direction in developing natural medicinal ingredients, a global trend alongside modern pharmaceuticals. The center also serves as an ideal venue for developing eco-tourism and medical tourism, which are gaining popularity.
Additionally, Imexpharm is advancing the construction of a Cephalosporin antibiotic factory in the Vietnam-Singapore Industrial Park in Bình Dương Province. Once operational, the facility will produce a variety of high-quality, next-generation antibiotics, many of which are currently imported.